Haoxi Health Technology (HAO) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
30 Sep, 2026Executive summary
The company operates as a holding entity with its main business conducted through a wholly owned PRC subsidiary, focusing on online marketing solutions for healthcare advertisers in China.
Revenue is generated from providing one-stop online marketing services, especially short video ads, with a client base primarily in the healthcare sector.
The company experienced significant revenue volatility over the past three years, with a sharp increase in FY2026 but a swing from net income to a substantial net loss.
The business is highly dependent on a single supplier, Ocean Engine (ByteDance), and faces intense competition and regulatory risks in China.
The company completed several equity financings and share structure changes, including multiple reverse splits and an increase in Class B share voting rights.
Financial highlights
FY2026 revenue was $54.83 million, up 67% from $32.80 million in FY2025, which had declined 32% from $48.52 million in FY2024.
Net loss for FY2026 was $9.54 million, compared to net income of $3.88 million in FY2025 and $1.29 million in FY2024.
Gross margin declined to 1.15% in FY2026 from 2.83% in FY2025 and 5.67% in FY2024, due to higher costs and lower rebates from media partners.
General and administrative expenses rose sharply to $8.61 million in FY2026, mainly due to a $6.02 million allowance for credit losses and increased labor costs.
Cash and cash equivalents at June 30, 2026 were $10.93 million, with net cash used in operating activities of $2.57 million and net cash provided by financing activities of $9.32 million.
The company recognized a $1.5 million impairment loss on intangible assets in FY2026 and a $6.07 million allowance for credit losses.
Outlook and guidance
Management expects continued investment in R&D and technology, particularly in its Bidding Compass software, and plans to expand its advertiser base in the healthcare sector.
The company does not anticipate paying dividends in the foreseeable future, prioritizing business expansion and liquidity.
Capital expenditures are expected to increase moderately over the next two to three years to support business growth.
Latest events from Haoxi Health Technology
- Registering up to $80M in securities, with strong revenue growth and high PRC regulatory risk.HAO
Registration Filing - Raising up to $80M on Nasdaq, the company targets healthcare marketing in China amid regulatory risks.HAO
Registration Filing - Raising $9.09M to expand healthcare-focused digital marketing in China, but faces regulatory and concentration risks.HAO
Registration Filing - IPO funds will drive growth and tech investment, but regulatory and supplier risks remain high.HAO
Registration Filing - Chinese healthcare-focused ad tech firm seeks $11.4M via Nasdaq unit offering, CEO retains control.HAO
Registration Filing - Offering 2,093,802 units at $5.97 each, the company targets healthcare ads but faces regulatory and concentration risks.HAO
Registration Filing - Rapid revenue growth, high regulatory risk, and CEO control define this complex offering.HAO
Registration Filing - FY2025 revenue fell 32% while net income surged to $3.88M, with ongoing regulatory and supplier risks.HAO
Q4 2024 - All AGM proposals, including share consolidation and director re-elections, passed with over 99% approval.HAO
AGM 2025